Cancer United

Cancer United is a clinical-stage biotechnology company focused on developing next-generation precision oncology treatments by targeting the tumor microenvironment and metabolic pathways. The company's lead program, CU-101, is a first-in-class dual inhibitor of monocarboxylate transporters 1 and 4 (MCT1/4) designed to disrupt lactate transport and metabolic symbiosis in solid tumors. By leveraging its proprietary metabolic reprogramming platform, Cancer United aims to overcome drug resistance and improve outcomes for patients with difficult-to-treat cancers. The company maintains operations in both the United States and China, facilitating global clinical development and strategic partnerships. Cancer United is currently advancing its lead candidate through Phase 1/2 clinical trials for various solid tumor indications.